CHRS Stock Recent News

Small-cap stocks took the brunt of the 2022 bear market and many names have yet to recover. Agenus and Coherus BioSciences are prime examples.

Few investors were impressed by the biotech's third-quarter performance. This included several analysts, one of whom went as far as to downgrade his recommendation.

Coherus BioSciences recently received US approval for toripalimab, but the stock is down 30% since July. The company's acquisition of Surface Oncology adds to its risk profile and raises concerns. CHRS has a market cap of $353mn and expects at least $275 million in net sales for the year.

Coherus delivered weaker-than-expected revenue and earnings for the third quarter. It also lowered its revenue outlook for the year, blaming delays in its planned commercial launches for Udenyca OnBody and Loqtorzi.

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - President, CEO and Chairman Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Yigal Nochomovitz - Citigroup Michael Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Christopher Schott - JPMorgan Ash Verma - UBS Operator Good day and thank you for standing by.

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after market close on Monday, November 6, 2023. Starting at 5:00 p.m. ET on November 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus and Chinese partner Junshi Biosciences announced U.S. FDA approval of Loqtorzi in all lines of treatment for nasopharyngeal carcinoma (NPC). Coherus management has insisted they will "not engage in heavily discounted pricing" for the drug.

Coherus announced it has resubmitted a biologic license application for one of its products. The FDA had previously issued a complete response letter holding up the product's approval, citing an ongoing review at a manufacturing site.

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.